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Cancer metastasis is a primary cause of cancer death. Antrodia cinnamomea (A. cinnamomea), a medicinal mushroom in Taiwan,
has shown antioxidant and anticancer activities. In this study, we ﬁrst observed that ethanol extract of fruiting bodies of A. cinna-
momea (EEAC) exerted a concentration-dependent inhibitory eﬀect on migration and motility of the highly metastatic CL1-5 cells
in the absence of cytotoxicity. The results of a gelatin zymography assay showed that A. cinnamomea suppressed the activities of
matrix metalloproteinase-(MMP-) 2 and MMP-9 in a concentration-dependent manner. Western blot results demonstrated that
treatmentwithA.cinnamomeadecreasedtheexpressionofMMP-9andMMP-2;whiletheexpressionoftheendogenousinhibitors
oftheseproteins,thatis,tissueinhibitorsofMMP(TIMP-1andTIMP-2)increased.FurtherinvestigationrevealedthatA.cinnamo-
mea suppressed the phosphorylation of ERK1/2, p38, and JNK1/2. A. cinnamomea also suppressed the expressions of PI3K and
phosphorylation of Akt. Furthermore, treatment of CL1-5 cells with inhibitors speciﬁc for PI3K (LY 294002), ERK1/2 (PD98059),
JNK (SP600125), and p38 MAPK (SB203580) decreased the expression of MMP-2 and MMP-9. This is the ﬁrst paper conﬁrming
the antimigration activity of this potentially beneﬁcial mushroom against human lung adenocarcinoma CL1-5 cancer cells.
1.Introduction
Lung cancer has been the leading cause of cancer-related
mortality worldwide. In some countries, it has become the
number one cancer cause of death, accounting for more
fatalities than prostate cancer, breast cancer, and colorectal
cancercombined[1].Humanlungadenocarcinomacelllines
CL1-0, CL1-1, CL1-5, and CL1-5-F4 are a series of sub-
lineswithprogressivelyinvasiveabilityestablishedbyinvitro
invasion screening. CL1-5 cells are a human lung adeno-
carcinoma cell line derived from the parental CL1 cells by
ﬁve successive Matrigel selections. CL1-5 cells showed a 4-
to 6-fold higher invasive ability than the parental cells and
their production of 92-kDa MMP-9 also exhibited a drastic
increase over that of their parental cells.
Metastasis is a characteristic of highly malignant cancers
with poor clinical outcome. Malignant tumor progression
depends upon the capacity to invade, metastasize, and pro-
mote the angiogenic host response. One critical characteris-
tic that metastatic cancer cells have acquired is the ability to
dissolve basement membranes and the extracellular matrix
(ECM). This degradative process is mediated largely by
matrix metalloproteinases (MMPs), which are a large family
of at least 20 zinc-dependent neutral endopeptidases that2 Evidence-Based Complementary and Alternative Medicine
together can degrade all known components of ECM [2].
MMP-9 is abundantly expressed in various malignant tu-
mors and is postulated to play a critical role in tumor inva-
sion and angiogenesis [3]. Thus, the inhibition of MMP
activity, including MMP-9, is important for the prevention
of cell invasion. CL1-5 cells, a human lung adenocarcinoma
cell line, expressed an elevated level of MMP-2, MMP-9
and exhibited a highly invasive and metastatic ability [4, 5].
Meanwhile,theactivityofMMPsispronetotheinhibitionof
endogenous tissue inhibitor of metalloproteinases (TIMPs),
which are speciﬁc inhibitors of MMPs, and the imbalance
betweenMMPsandTIMPsmaycontributetodegradationor
deposition of ECM [6]. The mitogen-activated protein kina-
ses (MAPKs) play an important regulatory role in cell
growth, diﬀerentiation, apoptosis, and metastasis [7]. In ad-
dition, phosphatidylinositol-3-kinase/serine/threonine pro-
tein kinase (or protein kinase B) (PI3K/Akt) signal trans-
ductionpathwayisinvolvedinthedevelopment,progression,
and metastasis of various tumors [8–10].
Traditionally, Antrodia cinnamomea (A. cinnamomea;
also named niu-chang-chih in Chinese) has been used as
a health food to prevent inﬂammation, hypertension, itchy
skin, and liver cancer [11]. There is increasing evidence
that A. cinnamomea possesses an extensive range of bio-
logical activities, including the liver protection [12], anti-
inﬂammation [13], and antioxidation [14]. Some reports
have suggested that extracts of mycelia and fruiting bodies
of A. cinnamomea could be a potential chemotherapeutic
agent against hepatoma, as well as prostate, breast, bladder,
and lung cancer cells [15–20], the antimetastatic eﬀect of
A. cinnamomea in lung adenocarcinoma CL1-5 cancer cells
is still unclear. In the present study, we investigated the
antimetastatic eﬀects of A. cinnamomea on a highly metas-
tatic CL1-5 cell lines as well as the underlying mechanisms.
2.MaterialsandMethods
2.1. Chemicals. A. cinnamomea was kindly provided by Cos-
mox Biomedical Co. Ltd. (Taoyuan, Taiwan). RPMI Medium
1640, 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide (MTT), LY294002, SP600125, and SB203580 were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
PD98059 was purchased from Cell Signaling Technology
(Beverly, MA, USA). Trypsin−EDTA, fetal bovine serum
(FBS), and penicillin/streptomycin were from Gibco Life
Technologies, Inc. (Paisley, UK). Cell culture supplies were
purchased from Costar (Corning, Inc., Cypress, CA, USA).
The antibody against AKT, Rac-1, MAPK/extracellular sig-
nal-regulated kinase (ERK) 1/2, c-Jun NH2-terminal kinase
(JNK)/stress-activated protein kinase, and p38 MAPK pro-
teins and phosphorylated proteins were purchased from Cell
Signaling Technology (Beverly, MA, USA). Anti-ERK1/2,
anti-PI3K, antifocal adhesion kinase (FAK), anti-p-FAK,
and horseradish peroxidase-conjugated goat anti-mouse IgG
antibody were purchased from Santa Cruz Biotechnology
Co. (Santa Cruz, CA, USA), β-actin was purchased from
Chemicon (Temecula, CA, USA).
2.2. Preparation of Ethanol Extract of Fruiting Bodies of A. cin-
namomea (EEAC). The fruiting body of A. cinnamomea was
kindly provided by Cosmox Biomedical Co. LTD (Taoyuan,
Taiwan) and identiﬁed by Dr. Chao-Lin Kuo (School of
Chinese Pharmaceutical Sciences and Chinese Medicine
Resource, Taiwan). A. cinnamomea was weighed about 1kg
and soaked in 10L of 95% ethanol solution (extractive sol-
vent) for 3 days at room temperature. The solid residue of
the above soaked herbs was ﬁltered and discarded through
a Buchner funnel lined with Whatman ﬁlter paper, and the
ﬁltrate was concentrated to paste by vacuum distillation
using the rotary evaporator (N-11, EYELA; Tokyo, Japan)
and vacuum controller (VC-760, TAKARA; Tokyo, Japan) to
maintain the desired pressure and temperature at 25◦Cw i t h
40mmHg. The various concentration of EEAC was further
diluted with DMSO for the further use.
2.3.CellCulture. CL1-5celllineswerekindlyprovidedbyDr.
W.-S. Wayne Chang (National Institute of Cancer Research,
National Health Research Institutes, Miaoli, Taiwan). The
cells were cultured in RPMI-1640 medium (Gibco, Grand
Island, NY, USA) with 10% fetal bovine serum (FBS, Gibco)
at 37◦C in a humidiﬁed atmosphere of 5% CO2.
2.4. Cytotoxicity Assay. The cells (1 × 105 cells/mL) were cul-
tured in 96-well plate containing RPMI-1640 supplemented
with10%FBSfor24htobecomenearlyconﬂuent.Thencells
were cultured with EEAC for 24h and 36h. Then, the cells
were washed twice with PBS and incubated with 100μLo f
0.5mg/mLMTTfor3hat37 ◦C, testing for cell viability. The
medium was then discarded and 50μL of dimethylsulfoxide
(DMSO) was added. After 10min incubation, absorbance at
590nm was read by a microplate reader.
2.5. Wound-Healing Assay. For cell motility determination,
CL1-5 cells (2 × 105 cells/mL) were seeded in a 12-well
tissue culture plate and grown to 80−90% conﬂuence. After
aspiration of the medium, the center of the cell monolayers
was scraped with a sterile micropipette tip to create a denu-
ded zone (gap) of constant width. Subsequently, cellular
debris was washed with PBS, and CL1-5 cells were exposed
to various concentrations of EEAC (0, 0.125, 0.25, 0.5,
and 1.0μg/mL). Wound closure was monitored and photo-
graphed at 0h and 36h with a Nikon inverted microscope.
Toquantifythemigratedcells,picturesoftheinitialwounded
monolayers were compared with the corresponding pictures
of cells at the end of the incubation. Artiﬁcial lines ﬁtting the
cutting edges were drawn on pictures of the original wounds
and overlaid on the pictures of cultures after incubation.
Cells that had migrated across the white lines were counted
in six random ﬁelds from each triplicate treatment.
2.6. Cell Migration Assay. T u m o rc e l lm i g r a t i o nw a sa s s a y e d
in transwell chambers (Millipore) according to the method
reported by Weng et al. [6] with some modiﬁcations. Brieﬂy,
transwell chambers with 6.5mm polycarbonate ﬁlters of
8μm pore size were used. CL1-5 cells (1 × 104 cells/mL) and
0, 0.125, 0.25, 0.5, and 1.0μg/mL of EEAC were suspended
in RPMI-1640 (100μL, serum free), placed in the upperEvidence-Based Complementary and Alternative Medicine 3
transwell chamber, and incubated for 24h at 37◦C. Then, the
cells on the upper surface of the ﬁlter were completely wiped
away with a cotton swab, and the lower surface of the ﬁlter
was ﬁxed in methanol, stained with Giemsa, and counted
under a microscope at a magniﬁcation of 200x. For each
replicate, the tumor cells in 10 randomly selected ﬁelds were
determined and the counts were averaged.
2.7. Determination of MMP-2 and MMP-9 by Zymography.
MMPsinthemediumreleasedfromCL1-5cellswereassayed
usinggelatinzymography(8%zymogramgelatingels)accor-
dingtothemethodsreportedbyWengetal.withsomemodi-
ﬁcation [6]. Brieﬂy, the culture medium was electrophoresed
(80V for 120min) in a 8% SDS-PAGE gel containing 0.1%
gelatin. The gel was then washed at room temperature in
a solution containing 2.5% (v/v) Triton X-100 with two
changes and subsequently transferred to a reaction buﬀer for
enzymatic reaction containing 1% NaN3,1 0m MC a C l 2 and
40mMTris-HCl,pH8.0,at37◦Cwithshakingovernight(for
12−15h). Finally, the MMP gel was stained for 30min with
0.25% (w/v) Coomassie blue in 10% acetic acid (v/v) and
20% methanol (v/v) and destained in 10% acetic acid (v/v)
and 20% methanol (v/v).
2.8. Western Blotting Analysis. Whole-cell lysates proteins
(40μgofpartiallypuriﬁedprotein)weremixedwithanequal
volume of electrophoresis sample buﬀer, and the mixture
was then boiled for 10min. Then, an equal protein content
of total cell lysate from control and EEAC-treated sample
were resolved in 12% SDS-PAGE gels. Proteins were then
transferred onto nitrocellulose membranes (Millipore, Bed-
ford, MA, USA) by electroblotting using an electroblotting
apparatus (Bio-Rad). Nonspeciﬁc binding of the membranes
was blocked with phosphate-buﬀered saline (PBS) contain-
ing 1% (w/v) nonfat dry milk and TBS-T buﬀer (Tris-Buﬀer
Saline with 0.1% (v/v) Tween 20) for more than 2h. Mem-
branes were washed with TBS-T buﬀer three times each for
10min and then incubated with an appropriate dilution of
speciﬁcprimaryantibodiesinTBS-Tbuﬀerovernightat4◦C.
The membranes were washed with TBS-T buﬀer and then
incubated with an appropriate secondary antibody (horse-
radish peroxidase-conjugated, goat anti-mouse, or anti-rab-
bit IgG) for 1h. After washing the membrane three times for
1 0m i ni nT B S - Tb u ﬀer, the bands were visualized using ECL
reagents (Millipore, Billerica, MA, USA). Band intensity on
scanned ﬁlms was quantiﬁed using Kodak Molecular Imag-
ing (MI) software and expressed as relative intensity com-
pared with control.
2.9. Statistical Analysis. V a l u e sa r ee x p r e s s e da sm e a n s± SD
and analyzed using one-way ANOVA followed by LSD test
for comparisons of group means. All statistical analyses were
performed using SPSS for Windows, version 10 (SPSS, Inc.);
a P value <0.05 is considered statistically signiﬁcant.
3. Results
3.1. Cytotoxicity of EEAC to CL1-5 Cells. The eﬀect of EEAC
(0−128μg/mL) on cell viability was determined by the MTT
assay.Afterincubationfor24hand36h,cellviabilitywasnot
signiﬁcantly aﬀected by EEAC (0.125−1.0μg/mL), as com-
pared to the untreated control (Figure 1(a)), indicating that
EEAC is not toxic to CL1-5 cells at these concentrations.
When cells were treated with EEAC at 1.0–128μg/mL for
24h and 36h, cell viability was signiﬁcantly decreased.
EEAC (0.125–1.0μg/mL) were also evaluated their apoptotic
eﬀect with ﬂow cytometry, and SubG1 was not signiﬁcantly
aﬀectedbyEEAC(0.125−1.0μg/mL),ascomparedtotheun-
treated control (Figure 1(b)). To avoid inhibition of cell via-
bility in the following experiments, we chose to use EEAC
concentrations between 0.125 and 1.0μg/mL and an incuba-
tion time of 36h.
3.2. Eﬀect of EEAC on Wound-Healing Assay. We further as-
sessed the eﬀect of EEAC on the migration of CL1-5 cells
using the wound healing assay in which the conﬂuent mono-
layer was scraped with a sterile micropipette tip to create
a scratch wound. As shown in Figure 2(a), EEAC inhibited
the migration of CL1-5 cells in a dose-dependent manner,
with 27.7% and 40.1% inhibition at 0.5 and 1.0μg/mL after
incubation for 36h, respectively, (Figure 2(b)).
3.3. Eﬀect of EEAC on Migration of CL1-5 Cells In Vitro.
The transwell assay was used to investigate the migration
of CL1-5 cells at 24h after EEAC treatment. We found that
EEAC added at 0.125−1.0μg/mL signiﬁcantly decreased the
migration (Figures 3(a) and 3(b)) of CL1-5 cells and that
these eﬀects of EEAC were dose dependent.
3.4.EEACInhibitstheReleaseofMMP-2andMMP-9inCL1-5
Cells. To examine the possible antimigration mechanisms of
EEAC, we determined the activity of MMP-2 and MMP-9 in
culture media of CL1-5 cells by zymographic analysis. In the
absence of treatment, CL1-5 cells constitutively secreted high
levels of MMP-9 and MMP-2. Our results showed that EEAC
inhibited MMP-9 and MMP-2 activities in a concentration-
dependent manner (Figures 4(a) and 4(b)). These results
suggest that the antimigration eﬀect of EEAC is related to
the inhibition of the enzymatically degradative processes of
CL1-5 migration.
3.5. Inhibition by EEAC of MMP-2 and MMP-9. To examine
the possible antimigration mechanisms of EEAC, we deter-
mined the MMP-2 and MMP-9 expressions in culture media
of CL1-5 cells by Western blotting assay. Using Western blot-
ting, we analyzed the eﬀects of treating cells with various
concentration of EEAC for 36h on MMPs protein expres-
sion. Treatment of CL1-5 cells with EEAC induced notice-
able reductions in MMP-9 and MMP-2 protein expression
(Figure 5).
3.6. Eﬀect of EEAC on TIMP-1,TIMP-2, FAK, and Phosphary-
lated FAK (p-FAK) Expressions in CL1-5 Cells. To further
explore the modulation of pro-MMP activation by EEAC, we
determined TIMP-1/2 protein expression levels. As shown in
Figure 5, EEAC strongly increased TIMP-1 and TIMP-2 acti-
vity in a concentration-dependent manner. To evaluate the4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) Viability of CL1-5 cells incubated with EEAC (0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16, 32, 64, and 128μg/mL) for 24h and 36h.
Cell viability was measured using MTT assay and is expressed as % of cell survival relative to control. (b) Flow cytometric analysis of EEAC
on the cell cycle of CL1-5. All the cells were treated with 1% fetal bovine serum with the addition of EEAC at 0.125μg/mL, 0.25μg/mL,
0.5μg/mL, and 1.0μg/mL for 36h. The value on the x-axis represents the DNA content, while the shaded area indicates the percentage of
cells at the S phase. Percentage of sub G1 contents in CL1-5 cells treated with EEAC. Values are means of three separate experiments, with
standard deviation represented by vertical bars.
∗P < 0.05;
∗∗P < 0.01. Lower case for 24h and upper case for 36h.
eﬀect of EEAC on FAK and p-FAK protein expression, CL1-5
cells were treated with EEAC at 0, 0.125, 0.25, 0.5, and
1.0μg/mL for 36h. As shown in Figure 5, EEAC suppressed
p-FAK expression in CL1-5 cells, when EEAC concentration
was higher than 0.25μg/mL.
3.7. Eﬀect of EEAC on PI3K, AKT, Phosphorylated AKT
(pAKT), and Rac-1 Expressions in CL1-5 Cells. PI3Ks are
a group of ubiquitously expressed lipid kinases which are
important players in a major pathway of cell signaling. The
PI3K/AKT pathway has been identiﬁed as a major regulator
of cellular proliferation, diﬀerentiation, and death in multi-
ple cell types [18]. To further investigate the involvement of
PI3K/AKT,aseriesofexperimentswasperformedtomeasure
the expression of candidate signaling molecules upon EEAC
stimulation. The results showed that incubation of CL1-5
cells with EEAC (0.125–1.0μg/mL) led to a dose-dependent
decreaseofPI3KandpAKTlevels(Figure 6).Similarly,EEAC
(0−1.0μg/mL,36h) suppressed Rac-1 protein expression in
a concentration-dependent manner, and the eﬀect became
statistically signiﬁcant when EEAC concentration was higher
than 0.25μg/mL (Figure 6).Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of EEAC on wound healing migration of CL1-5 cells. Wound was introduced by scraping conﬂuent cell layers with a pipet
tip. CL1-5 cells were incubated with EEAC (0.125, 0.25, 0.5, and 1.0μg/mL) for 36h, and the migration distances of cells were calculated.
(a) Representative photographs of invading cells that received either control or EEAC treatment. (b) Migrated cells across the black lines
were counted in six random ﬁelds from each treatment. The mean number of cells in the denuded zone is quantiﬁed by three independent
experiments. Values (means ± SD, n = 3) diﬀer signiﬁcantly (P<0.05).
3.8. Inhibition by EEAC of Phosphorylated FAK, ERK1/2, p38,
and JNK1/2. We analyzed the phosphorylation of MAPKs in
CL1-5 cells after treatment with EEAC (0.125−1.0μg/mL)
for 36h. Data in Figure 7 showed that EEAC signiﬁcantly
dose-dependentlyaﬀectp-FAK,p-ERK1/2,p-JNK1/2,orp38
and p-p38 proteins at concentrations from 0.125–1.0μg/mL.
3.9. Speciﬁc Inhibitor to Analyze the Signaling Transduction.
To further delineate whether the inhibition of cell migration
by EEAC occurs through inhibition of PI3K, ERK, JNK, and
p38 signaling, CL1-5 cells were 1h pretreated with a PI3K
inhibitor (LY294002; 50μM), ERK1/2 inhibitor (PD98059;
50μM), JNK inhibitor (SP600125; 50μM), p38 MAPK inhi-
bitor (SB203580; 50μM), and then incubated in the presence
or absence of EEAC (1.0μg/mL) for 36h. The Western blot-
ting assay revealed that EEAC or LY294002 (50μM), PD98-
256 (50μM), SP600125 (50μM), SB203580 (50μM) alone
decreased MMP-9 and MMP-2 protein expressions. Further-
more,thecombinedtreatment(50μM,LY294002,SB203580,
SP600125 and PD98059 plus 1.0μg/mL EEAC) resulted in
enhanced inhibition of MMP-9 and MMP-2 (Figure 7(b)).
4. Discussions
SeveralcancercelllinesincludingA498,NPC-TW01,Hep3B,
HepG2,TW206,CL1-0,andCL1-5havebeenscreedfortheir
cell cytotoxicity at 12, 24, 36, and 48h. Our results showed
that CL1-0 (IC50 = 16μg/mL) and CL1-5 (IC50 = 16μg/mL)
exhibits more susceptible to EEAC than other cells for 36h
exposure. As CL1-5 cells showed higher metastatic ability, we
explored the antimigration eﬀects and mechanistic actions
of EEAC in human lung adenocarcinoma CL1-5 cells. Our
results demonstrate that EEAC signiﬁcantly inhibited the
migration(assessedusingthetranswellassayandthewound-
healing assay) of CL1-5 cells (Figures 2 and 3). We also
showed that EEAC remarkably inhibited the activities of
MMP-2 and MMP-9 (Figure 4). These results demonstrated
that the antimetastastic eﬀect of EEAC was associated with
the inhibition of enzymatically degradative processes of
smooth muscle cells migration. To our knowledge, it is the
ﬁrststudytodemonstratethatEEACreducesthebiochemical
mechanisms of the migration in CL1-5 cells.
Several bioactive compound from the ethanol extract
of A. cinnamomea, such as antroquinonol, 4-acetylantro-
quinonol B, and zhankuic acid A, have been reported to
reduce cell proliferation of hepatoma, colon and leukemia
cancer cells [21–23]. Ourprevious studies demonstrated that
the marked compounds (i.e., adenosine, cordycepin, and
zhankuic acid A) within EEAC were identiﬁed by HPLC and
LC/MS/MS to be as indicator compounds for quality check
of extraction procedure of each batch (data not shown).
Accordingtotherelativeconcentrationofexternalstandards,
the content of adenosine, cordycepin and zhankuic acid A
were calculated to be 0.08, 0.16, and 235mg/g EEAC, res-
pectively, (data not shown). Of these, adenosine might be
through binding to adenosine A3 receptors (A3-AR) to dec-
rease the telomeric signal, resulting in G0/G1 arrest of lym-
phoma cell. Moreover, A3 receptor antagonist cotreated with
cordycepin would reverse cordycepin-induced in mouse Ley-
dig tumor cell death, which indicate the possible relationship
between A3-AR and cordycepin-induced death eﬀect [24,
25]. Wu et al. indicated that cordycepin could induce cell
arrest at G2/M and subG1 phases followed by signiﬁcant
apoptotic cell death in human OEC-M1 oral cancer cell line
[26]. Similarly, cordycepin has also been found to cause
G2/M arrest in human bladder and colon cancer cells
through upregulation of p21WAF1 l e v e la sw e l la sr e d u c t i o no f
cyclin B1, Cdc2, and Cdc25c proteins in a p53-independent
manner by regulating c-Jun N-terminal kinase activation
[27, 28]. Furthermore, Geethangili and Tzeng reported that
zhankuic acid A exhibited cytotoxic activity against P-388
murine and leukemia cells with an IC50 value of 1.8 and
5.4μg/mL, respectively, [29].
During cancer progression, certain tumor cells become
motile and attack the host tissue leading to metastasis.
Focal adhesion kinase (FAK) can be activated in response to
various stimuli and plays an important role in the cancer6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of EEAC on (a) transwell migration assay of CL1-5 cells. CL1-5 cells were incubated with EEAC (0.25, 0.5 and 1.0μg/mL)
for 24h and 36h, and the (b) transwell migration cells were calculated. Photos of the migration CL1-5 cells were taken under a microscope
(200-fold magniﬁcation). Values (means ± SD, n = 3) diﬀer signiﬁcantly (P<0.05).
cell proliferation and metastasis [30]. Compiling evidence
implies that FAK regulates focal adhesion signaling by phos-
phorylating various substrates and by acting as a scaﬀold
for protein-protein interactions, as well as the MMPs-medi-
ated matrix degradation, which consecutively regulates
downstreamsignalingcascades[31].FAK,acytoplasmickin-
ase that is involved in ECM and integrin-mediated signaling
pathways, has been suggested to have an essential role in
metastasis through the modulation of tumor cell migration
and invasion [32]. Majorly, integrin-mediated FAK signaling
isphosphorylationofTyr397.Particularly,phosphorylationof
Tyr397 forms a high-aﬃnity binding site for Src-homology
domain 2 (SH2), domains of Src family kinase, therefore
promotingSrckinaseactivity.Asaresult,amajorfunctionof
FAK is to recruit and activatr Src at cell-extracellular matrix
adhesion sites. Activated FAK in cancer cells relays signals
through multiple downstream targets. For example, activa-
ted FAK binds the SH2 of PI3K, thereby transporting the
catalyticsubunitofPI3Ktothemembrane,whereitcatalyzes
the phosphorylation of inositol lipids in lung cancer cell
migration [33]. The residues surrounding Tyr397 can also
constituteasequencethatbindstotheRassignalingpathway.
ThedownstreamtargetsoftheRassignalingpathwayinclude
ERK1/2 [34]. Indeed, these pathways are activated during
integrin binding to the ECM, resulting in the transduction
of external stimuli from the ECM to the nucleus [35]. Cer-
tain result suggests that anti-invasive eﬀect in androgen-in-
dependent prostate cancer by controlling MMP-9 expression
through the suppression of the EGFR/JNK pathway [36].
FAK and MAPK signaling involved in MMP-2 secretion has
been shown in QG90 lung cancer cells [37]. Moreover, it was
found that the MMP-9 gene promoter is partially regulated
through activation of the ERK1/2 pathway [38]. In recent,
p38 is implicating mediating bladder cancer invasion via
regulationofMMP-2andMMP-9atthelevelofmRNAstabi-
lity [39]. Also, p38γ MAPK activates c-Jun, and the activated
c-Jun recruits p38γ as a cofactor into MMP-9 promoter to
induce its trans-activation and cell invasion [40]. In this
study,wefoundthatEEACinhibitedtheactivationofFAK,as
evidenced by reduced phosphorylation of FAK (Figure 7(a)).
We also demonstrated that treatment with EEAC inhibited
phosphorylation of ERK1/2, phospho-p38, and JNK1/2 acti-
vity (Figure 7(a)). The use of speciﬁc inhibitors revealed that
PI3K, ERK, JNK, and p38 play important roles in regulating
cell death induced by EEAC in CL1-5 cells (Figure 7(b)). In
this study, the Western blotting assay was used to examine
the eﬀects of speciﬁc MAPK inhibitors, as the same method
has often been used to examine the eﬀects of speciﬁc MAPKEvidence-Based Complementary and Alternative Medicine 7
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Figure 4:EﬀectsofEEAConMMP-2andMMP-9activitiesofCL1-
5 cells. (a) Cells were treated with various concentrations (0.125,
0.25, 0.5, and 1.0μg/mL) of EEAC for 36h. The conditioned media
were collected, and MMP-2, and MMP-9 activities were determined
bygelatinzymography.(b)Theactivitiesoftheseproteinsweresub-
sequentlyquantiﬁedbydensitometricanalysis.Values(means ±SD,
n = 3) diﬀer signiﬁcantly (P<0.05) (lower case for MMP-2 and
upper case for MMP-9).
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Figure 5:EﬀectsofEEAConTIMP-1,TIMP-2,MMP-9,andMMP-
2 protein expression. CL1-5 cells were treated with 0.125, 0.25, 0.5,
and 1.0μg/mL for 36h, and cell lysates were subjected to SDS-
PAGE followed by western blotting and subsequently quantiﬁed by
densitometric analyses (using control as 100%). The values indicate
the density proportion of each protein compared with control.
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Figure 6: Concentration-dependent eﬀects of EEAC on the protein
expression level of PI3K, phosphorylated AKT and Rac-1. In the
concentration-dependentassay,CL1-5cellsweretreatedwith0.125,
0.25, 0.5, and 1.0μg/mL of EEAC for 36h. The expression of PI3K,
phosphorylation of AKT and Rac-1 were analyzed by Western blot-
ting. β-actin was used as a loading control. The values indicate the
density proportion of each protein compared with control.
inhibitors [6]. Therefore, it appears that FAK can promote
CL1-5 cancer cell migration through the MAPK signaling
and MMP-2 and MMP-9 pathway.
In addition, we showed that EEAC inhibited PI3K/AKT
in CL1-5 cells. Thus, it seems that FAK promotes CL1-5
cancer cell migration in concert with the activation of the
PI3K/AKT signaling pathways. Increased phosphorylation
of FAK and its downstream targets, Src, ERK1/2, PI3K,
and AKT have been shown in A549 lung epithelial cells
stimulated by ﬁbronectin. Consistent with this observation,
depletion of FAK by siRNA resulted in the inhibition of Src,
ERK1/2, PI3K, and AKT activity [33]. Several studies have
indicated that FAK/PI3K/Akt is involved in the regulation
of MMP-2 and MMP-9 activities on diﬀerent cell types
[9,41].Shibataetal.[42]haveshownthatstimulatedovarian
cancer cells with ﬁbronectin activated MMP-9 secretion,
while both antisense oligonucleotide to FAK and dominant-
negative mutation of Ras abolished this phenomenon. To
assess whether EEAC inhibits the phosphorylation of FAK,
AKT, and the protein level of PI3K, CL1-5 cells were treated
with various concentrations of EEAC (0.125, 0.25, 0.5, and
1.0μg/mL) for 36h. Figure 6 showed EEAC signiﬁcantly
inhibited the activation of FAK and AKT as shown by the
decrease in the phosphorylation of FAK and AKT. In ad-
dition, EEAC inhibited the protein levels of PI3K in a dose-
dependent manner (Figure 6). Zeng et al. [43] reported that
activated FAK-induced PI3K is required for the production
of matrix metalloproteinases (MMPs). Also, PI3K is one of
the critical downstream signal molecules of FAK pathways
[44]. Therefore, our results demonstrated that EEAC inhib-
ited the expressions of p-FAK, pAKT, and PI3K.
The Rho family of small guanosine triphosphatases
(GTPases)(includingRhoA,RhoB,c-Raf,Rac-1,andCdc42)
are critical in regulating actin reorganization associated with
cell growth, migration, transformation, and gene expression8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Eﬀects of EEAC on protein levels of MAPK signaling and phosphorylated focal adhesion kinase (p-FAK) in CL1-5 cells. (a) CL1-5
weretreatedwithseveraldiﬀerentconcentrationsofEEAC(0.125,0.25,0.5,and1.0μg/mL)f o r36h.(b)EﬀectsofPI3Kinhibitor(LY294002;
50μM), ERK1/2 inhibitor (PD98059; 50μM), JNK inhibitor (SP600125; 50μM), and p38 MAPK inhibitor (SB203580; 50μM) on EEAC-
induced protein expressions of MMP-2 and -9. Cells were pretreated with an inhibitor (50μM) at 1h prior to the treatment with 1.0μg/mL
EEAC for 36h (total inhibitor exposure time was 37h). Protein expressions of MMP-2 and -9 were determined by the western blotting assay.
[45]. The Rho family of GTPases has been reported to be
involved in the regulation of the phosphatidylinositol 3-kin-
ase (PI3K)/AKT signaling pathway [46]. In addition, Camp-
bell et al. [9] reported that PI3K/AKT signal transduction
pathway regulates cell invasion and metastasis of nonsmall
cell lung cancer (NSCLC) and is closely associated with the
development and progression of various tumors. Rac1 was
reported to act as a downstream eﬀect of PI3-K in several
growth factor-stimulated pathways [47] and to induce inva-
sion and metastasis in cancer cells [48]. Rac1 activation also
played a critical role in the migration of cancer cells [49].
Rac-1 has been implicated in the regulation of the contrac-
tion and retraction forces that are required for cell migra-
tion [50]. Increased Rac-1 expression enhances the phos-
phorylation of myosin, which cross-links actin ﬁlaments and
generates contractile forces, promoting movement of the cell
body and facilitating cell rear detachment. Rac-1 is also im-
plicated in the invasion of human microvascular endothelial
cells. Active-Rac-1 could induce the expression of MMP-9
metalloproteinase and promote migration of endothelial
cells [51]. Rac-1 may exert this activity through upregulate
transcription factors such as NF-κB known to be involved
in the expression of certain metalloproteinases including
MMP-9. Our ﬁnding that EEAC concentration dependen-
tly decreased Rac-1 protein expression (Figure 6), suggest-
ing that EEAC may also inhibit the metastasis of CL1-5
cells through the PI3K/Akt—Rac-1 and Rac-1—MMP-9
pathways.
In conclusion, we have demonstrated that EEAC inhibits
the migration of human lung adenocarcinoma cancer CL1-5
cells. Mechanistically, we show that this eﬀect of EEAC may
occur through inactivation of the ERK1/2 signaling pathway,
exerting inhibitory eﬀects on FAK, p-FAK, and Rac-1 protein
expressions and inhibiting PI3K, and phospho-Akt levels,
thereby decreasing the activities of MMP-2, MMP-9 of CL1-
5 cells (Figure 8). Further preclinical and clinical studies are
required to demonstrate the potential of EEAC as an anti-
cancer agent.Evidence-Based Complementary and Alternative Medicine 9
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Figure 8: Proposed signaling pathways for EEAC-mediated inhibi-
tionagainstmigrationofCL1-5cells.TheeﬀectofEEACisachieved
likelythroughtheinhibitionofFAK,whichregulatesRac-1/MMP-9
expression through MAPK and PI3K/AKT signaling pathways.
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